R-ketorolac ameliorates cancer-associated cachexia and prolongs survival of tumour-bearing mice.
Sophia E ChrysostomouSandra EderIsabella PototschnigAnna-Lena MayerMartina DerlerMarion MussbacherSilvia SchauerDongxu ZhangDongmei YanGennie LiuGerald HoeflerThomas WeichhartPaul W VeselyLingbing ZhangMartina SchweigerPublished in: Journal of cachexia, sarcopenia and muscle (2024)
RK improved T-lymphopenia and decreased systemic IL-6 concentrations, resulting in alleviation of cachexia and increased survival of cachexigenic tumour-bearing mice, even under chemotherapy and independent of COX inhibition. Considering its potential, we propose that the use of RK should be investigated in patients suffering from CAC.
Keyphrases
- end stage renal disease
- high fat diet induced
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- free survival
- squamous cell carcinoma
- radiation therapy
- mouse model
- mass spectrometry
- type diabetes
- patient reported outcomes
- insulin resistance
- high resolution
- skeletal muscle
- drug induced
- atomic force microscopy
- high speed